Association Between CYP2D6 Genotypes and the Clinical Outcomes of Adjuvant Tamoxifen for Breast Cancer: A Meta-Analysis

• Early Breast Cancer Trialists‘ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet365(9472) , 1687–1717 (2005).
   PubMed Web of Science ®Google Scholar
• Boocock DJ , BrownK, GibbsAH, SanchezE, TurteltaubKW, WhiteIN. Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis23(11) , 1897–1901 (2002).
   PubMed Web of Science ®Google Scholar
• Crewe HK , NotleyLM, WunschRM, LennardMS, GillamEM. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4´-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab. Dispos.30(8) , 869–874 (2002).
   PubMed Web of Science ®Google Scholar
• Desta Z , WardBA, SoukhovaNV, FlockhartDA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther.310(3) , 1062–1075 (2004).
   PubMed Web of Science ®Google Scholar
• Coller JK , KrebsfaengerN, KleinK et al. The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br. J. Clin. Pharmacol. 54(2) , 157–167 (2002).
   PubMed Web of Science ®Google Scholar
• Fabian C , TilzerL, SternsonL. Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer. Biopharm. Drug Dispos.2(4) , 381–390 (1981).
   PubMed Web of Science ®Google Scholar
• Johnson MD , ZuoH, LeeKH et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res. Treat. 85(2) , 151–159 (2004).
   PubMed Web of Science ®Google Scholar
• Stearns V , JohnsonMD, RaeJM et al. Active tamoxifen metabolite plasma concentrations after co-administration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl Cancer Inst. 95(23) , 1758–1764 (2003).
   PubMed Web of Science ®Google Scholar
• Gjerde J , GandiniS, Guerrieri-GonzagaA et al. Tissue distribution of 4-hydroxy- N-desmethyltamoxifen and tamoxifen- N-oxide. Breast Cancer Res. Treat. 134(2) , 693–700 (2012).
   PubMed Web of Science ®Google Scholar
• Zanger UM , RaimundoS, EichelbaumM. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch. Pharmacol.369(1) , 23–37 (2004).
   PubMed Web of Science ®Google Scholar
• Bradford LD . CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics3(2) , 229–243 (2002).
   PubMed Web of Science ®Google Scholar
• Sachse C , BrockmollerJ, HildebrandM, MullerK, RootsI. Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine. Pharmacogenetics8(2) , 181–185 (1998).
   PubMedGoogle Scholar
• Sakuyama K , SasakiT, UjiieS et al. Functional characterization of 17 CYP2D6 allelic variants ( CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47–51, 53–55, and 57). Drug Metab. Dispos. 36(12) , 2460–2467 (2008).
   PubMed Web of Science ®Google Scholar
• Gaedigk A , GotschallRR, ForbesNS, SimonSD, KearnsGL, LeederJS. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics9(6) , 669–682 (1999).
   PubMedGoogle Scholar
• Del Re M , MichelucciA, SimiP, DanesiR. Pharmacogenetics of anti-estrogen treatment of breast cancer. Cancer Treat. Rev.38(5) , 442–450 (2012).
   PubMed Web of Science ®Google Scholar
• Aklillu E , PerssonI, BertilssonL, JohanssonI, RodriguesF, Ingelman-SundbergM. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J. Pharmacol. Exp. Ther.278(1) , 441–446 (1996).
   PubMed Web of Science ®Google Scholar
• Mürdter TE , SchrothW, Bacchus-GerybadzeL et al. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin. Pharmacol. Ther. 89(5) , 708–717 (2011).
   PubMed Web of Science ®Google Scholar
• Jin Y , DestaZ, StearnsV et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl Cancer Inst.97(1) , 30–39 (2005).
   PubMed Web of Science ®Google Scholar
• Irvin WJ , WalkoCM, WeckKE et al. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J. Clin. Oncol. 29(24) , 3232–3239 (2011).
   PubMed Web of Science ®Google Scholar
• Lim HS , Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J. Clin. Oncol.25(25) , 3837–3845 (2007).
   PubMed Web of Science ®Google Scholar
• Kiyotani K , MushirodaT, ImamuraCK et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J. Clin. Oncol. 28(8) , 1287–1293 (2010).
   PubMed Web of Science ®Google Scholar
• Park IH , RoJ, ParkS et al. Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment. Breast Cancer Res. Treat. 131(2) , 455–461 (2012).
   PubMed Web of Science ®Google Scholar
• Regan MM , Leyland-JonesB, BouzykM et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1–98 Trial. J. Natl Cancer Inst.104(6) , 441–451 (2012).
   PubMed Web of Science ®Google Scholar
• Rae JM , DruryS, HayesDF et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J. Natl Cancer Inst.104(6) , 452–460 (2012).
   PubMed Web of Science ®Google Scholar
• Thompson AM , JohnsonA, QuinlanP et al. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res. Treat. 125(1) , 279–287 (2011).
   PubMed Web of Science ®Google Scholar
• Schroth W , GoetzMP, HamannU et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302(13) , 1429–1436 (2009).
   PubMed Web of Science ®Google Scholar
• Okishiro M , TaguchiT, Jin Kim S, Shimazu K, Tamaki Y, Noguchi S. Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer115(5) , 952–961 (2009).
   PubMed Web of Science ®Google Scholar
• Xu Y , SunY, YaoL et al. Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann. Oncol. 19(8) , 1423–1429 (2008).
   PubMed Web of Science ®Google Scholar
• Sukasem C , SirachainanE, ChamnanphonM et al. Impact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: a microarray-based study in Thailand. Asian Pac. J. Cancer Prev. 13(9) , 4549–4553 (2012).
   PubMedGoogle Scholar
• Newman WG , HadfieldKD, LatifA et al. Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin. Cancer Res. 14(18) , 5913–5918 (2008).
   PubMed Web of Science ®Google Scholar
• Toyama T , YamashitaH, SugiuraH, KondoN, IwaseH, FujiiY. No association between CYP2D6*10 genotype and survival of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen treatment. Jpn J. Clin. Oncol.39(10) , 651–656 (2009).
   PubMed Web of Science ®Google Scholar
• Lash TL , Cronin-FentonD, AhernTP et al. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J. Natl Cancer Inst. 103(6) , 489–500 (2011).
   PubMedGoogle Scholar
• Lash TL , Cronin-FentonD, AhernTP et al. Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta Oncol. 49(3) , 305–312 (2010).
   PubMed Web of Science ®Google Scholar
• Goetz MP , SchaidDJ, WickerhamDL et al. Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials. Clin. Cancer Res. 17(21) , 6944–6951 (2011).
   PubMed Web of Science ®Google Scholar
• Teh LK , MohamedNI, SallehMZ et al. The risk of recurrence in breast cancer patients treated with tamoxifen: polymorphisms of CYP2D6 and ABCB1. AAPS J. 14(1) , 52–59 (2012).
   PubMed Web of Science ®Google Scholar
• Wegman P , VainikkaL, StalO et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res. 7(3) , R284–R290 (2005).
   PubMed Web of Science ®Google Scholar
• Wegman P , ElingaramiS, CarstensenJ, StalO, NordenskjoldB, WingrenS. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res.9(1) , R7 (2007).
   PubMed Web of Science ®Google Scholar
• Bijl MJ , van Schaik RH, Lammers LA et al. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res. Treat.118(1) , 125–130 (2009).
   PubMed Web of Science ®Google Scholar
• Abraham JE , MaranianMJ, DriverKE et al. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res.12(4) , R64 (2010).
   PubMed Web of Science ®Google Scholar
• Ramón y Cajal T , AltesA, PareL et al. Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res. Treat. 119(1) , 33–38 (2010).
   PubMed Web of Science ®Google Scholar
• Stingl JC , ParmarS, Huber-WechselbergerA et al. Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment. Curr. Med. Res. Opin. 26(11) , 2535–2542 (2010).
   PubMed Web of Science ®Google Scholar
• Damodaran SE , PradhanSC, UmamaheswaranG, KadambariD, ReddyKS, AdithanC. Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy. Cancer Chemother. Pharmacol.70(1) , 75–81 (2012).
   PubMed Web of Science ®Google Scholar
• Kiyotani K , MushirodaT, HosonoN et al. Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response. Pharmacogenet. Genomics 20(9) , 565–568 (2010).
   PubMed Web of Science ®Google Scholar
• Nowell SA , AhnJ, RaeJM et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res. Treat. 91(3) , 249–258 (2005).
   PubMed Web of Science ®Google Scholar
• Goetz MP , RaeJM, SumanVJ et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 23(36) , 9312–9318 (2005).
   PubMed Web of Science ®Google Scholar
• Goetz MP , KnoxSK, SumanVJ et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat. 101(1) , 113–121 (2007).
   PubMed Web of Science ®Google Scholar
• Schroth W , AntoniadouL, FritzP et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J. Clin. Oncol. 25(33) , 5187–5193 (2007).
   PubMed Web of Science ®Google Scholar
• Kiyotani K , MushirodaT, SasaM et al. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci. 99(5) , 995–999 (2008).
   PubMed Web of Science ®Google Scholar
• Seruga B , AmirE. Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-ana­lysis. Breast Cancer Res. Treat.122(3) , 609–617 (2010).
   PubMed Web of Science ®Google Scholar
• Normand SL . Meta-ana­lysis: formulating, evaluating, combining, and reporting. Stat. Med.18(3) , 321–359 (1999).
   PubMed Web of Science ®Google Scholar
• Davies C , GodwinJ, GrayR et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-ana­lysis of randomised trials. Lancet 378(9793) , 771–784 (2011).
   PubMed Web of Science ®Google Scholar
• Hackshaw A , RoughtonM, ForsythS et al. Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer. J. Clin. Oncol. 29(13) , 1657–1663 (2011).
   PubMed Web of Science ®Google Scholar
• Dowsett M , CuzickJ, IngleJ et al. Meta-ana­lysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J. Clin. Oncol. 28(3) , 509–518 (2010).
   PubMed Web of Science ®Google Scholar
• Cuzick J , SestakI, BaumM et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year ana­lysis of the ATAC trial. Lancet Oncol. 11(12) , 1135–1141 (2010).
   PubMed Web of Science ®Google Scholar
• Howell A , CuzickJ, BaumM et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years‘ adjuvant treatment for breast cancer. Lancet 365 , 60–62 (2005).
   PubMed Web of Science ®Google Scholar
• Thürlimann B , KeshaviahA, CoatesAS et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353 , 2747–2756 (2005).
   PubMed Web of Science ®Google Scholar
• Perez EA . Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann. Oncol.18(Suppl. 8) , 26–35 (2007).
   Web of Science ®Google Scholar
• Leung KM , ElashoffRM, AfifiAA. Censoring issues in survival ana­lysis. Annu. Rev. Public Health18 , 83–104 (1997).
   PubMed Web of Science ®Google Scholar
• Efron B , TibshiraniR. An Introduction to the Bootstrap. Chapman & Hall/CRC, London, UK (1993).
   Google Scholar
• Gonzalez-Santiago S , ZarateR, De La Haba-Rodriguez J, Gomez A, Bandres E, Borrega P. Genetic polymorphism CYP2D6(*4) interaction in clinical outcomes of tamoxifen-treated breast cancer patients. Ann. Oncol.17 , 62–63 (2006).
   Google Scholar
• Zeng Z , LiuY, LiuZ et al. CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-ana­lysis. Cancer Chemother. Pharmacol.72(2) , 287–303 (2013).
   PubMed Web of Science ®Google Scholar
• Bratherton DG , BrownCH, BuchananR et al. A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd. Br. J. Cancer 50(2) , 199–205 (1984).
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M , SimSC, GomezA, Rodriguez-AntonaC. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther.116(3) , 496–526 (2007).
   PubMed Web of Science ®Google Scholar
• Brauch H , SchrothW, GoetzMP et al. Eichelbaum M. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J. Clin. Oncol. 31(2) , 176–180 (2013).
   PubMed Web of Science ®Google Scholar
• Loo LW , TonC, WangYW et al. Differential patterns of allelic loss in estrogen receptor-positive infiltrating lobular and ductal breast cancer. Genes Chromosomes Cancer 47(12) , 1049–1066 (2008).
   PubMed Web of Science ®Google Scholar
• Castells A , GusellaJF, RameshV, RustgiAK. A region of deletion on chromosome 22q13 is common to human breast and colorectal cancers. Cancer Res.60(11) , 2836–2839 (2000).
   PubMed Web of Science ®Google Scholar
• Hirano A , UtadaY, HagaS et al. Allelic losses as prognostic markers for breast cancers. Int. J. Clin. Oncol. 6(1) , 6–12 (2001).
   PubMedGoogle Scholar
• Ahmad A , AliSM, AhmadMU, SheikhS, AhmadI. Orally administered endoxifen is a new therapeutic agent for breast cancer. Breast Cancer Res. Treat.122(2) , 579–584 (2010).
   PubMed Web of Science ®Google Scholar

▪ Websites

• CYP2D6 allele nomenclature (2013). www.cypalleles.ki.se/cyp2d6.htm (Accessed 16September2013)
   Google Scholar